Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of weekly oral BMS-275183 in pretreated non-small cell lung cancer
2004-000119-24Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2004
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bms-275183 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Tumor response rate. Started Oct 2004; status: completed.
02
Drugs
bms-275183
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-000119-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000119-24.